DWS CROCI® Equity Dividend Fund

Q4 | 12.31.25

Share Class: A I KDHAX C I KDHCX S I KDHSX INST I KDHIX

Objective

The fund seeks to achieve a high rate of total return.

Strategy

Portfolio management uses a systematic process to select approximately 40 companies among the large cap universe that offer economic value, as identified by the CROCI® Economic P/E, and above market median, sustainable dividend yield‡. CROCI® (Cash Return on Capital Invested) is a proprietary valuation methodology with origins in investment research conducted to identify attractively valued companies across sectors and geographic locations.

Expense ratio (as of latest prospectus)

Class	Net	Gross	Contractual Waiver
A	1.02%	1.02%	--
C	1.81%	1.86%	02/28/2027
S	0.78%	0.78%	--
INST	0.76%	0.76%	--

Without a waiver, returns would have been lower and any rankings/ratings might have been less favorable.

The CROCI® strategy is supplied by the CROCI® Investment Strategy and Valuation Group, a unit within the DWS Group, through a licensing arrangement with the fund's Advisor. The CROCI® valuation process is not managed or executed by DWS Investment Management Americas, Inc. (DIMA). The members of the CROCI® team are not employees of DIMA nor do they provide investment advisory services on behalf of DIMA.

Average annual total returns (as of 12/31/25)

Share class	YTD	1-year	3-year	5-year	10-year	Since inception	Inception date
Share classes with no sales charge							
S	3.70%	3.70%	7.58%	8.58%	9.42%	5.87%	2/28/05
INST	3.72%	3.72%	7.60%	8.63%	9.46%	6.90%	8/19/02
Russell 1000 Index[1]	17.37%	17.37%	22.74%	13.59%	14.59%	–	–
Russell 1000 Value Index[2]	15.91%	15.91%	13.90%	11.33%	10.53%	–	–
Unadjusted for sales charge (would be lower if adjusted)							
A	3.46%	3.46%	7.33%	8.34%	9.17%	9.58%	3/18/88
C	2.68%	2.68%	6.50%	7.49%	8.35%	7.22%	9/11/95
Adjusted for maximum sales charge							
A (max 5.75% load)	-2.49%	-2.49%	5.23%	7.07%	8.53%	9.41%	3/18/88
C (max 1.00% CDSC)	1.79%	1.79%	6.50%	7.49%	8.35%	7.22%	9/11/95

Historical total returns (as of 12/31/25)

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
S	3.70%	13.71%	5.59%	1.36%	19.60%	-9.31%	29.71%	-3.03%	19.55%	19.51%

Performance is historical and does not guarantee future results. Investment returns and principal fluctuate so your shares may be worth more or less when redeemed. Current performance may be lower or higher than the performance data quoted. Please visit www.dws.com for the fund's most recent month-end performance. Performance includes reinvestment of all distributions. Index returns assume reinvestment of all distributions and do not reflect fees or expenses. It is not possible to invest directly in an index. Not all share classes are available to all investors. A minimum investment of $1 million is required to open an account for Institutional shares. Adjusted Class C returns for periods of less than one year (e.g., YTD) reflect the Class C deferred sales charge of 1.00%. Adjusted Class C one-year returns do not reflect the effect of the 1.00% deferred sales charge and would be lower if an investor redeemed at the end of the one-year period and the deferred sales charge was applied.

‡ Please see prospectus for full description on the CROCI® investment process.

Portfolio and risk statistics[3] (12/31/25)

Fund inception date	3/18/1988
Number of holdings	42
Total net assets	$761 million
Beta§	0.59
Average market cap§	$38.7 billion
Sharpe ratio§	0.27
Standard deviation§	11.69

Portfolio management/industry experience

Di Kumble CFA	29 years
John Moody	27 years

Investment products: No bank guarantee | Not FDIC insured | May lose value

Fund information

Class	Symbol	CUSIP
A	KDHAX	25159G811
C	KDHCX	25159G746
S	KDHSX	25159G761
INST	KDHIX	25159G779

Fund details (fund data as of 12/31/25)

Fund inception date	3/18/1988
Total net assets	$761 million

Security type (12/31/25)

Common stocks	100%

Top equity holdings (12/31/25)

Merck	3.0%
Amgen	3.0%
Cabot Oil & Gas	2.9%
Bristol-Myers Squibb	2.9%
Devon Energy	2.9%
Medtronic	2.8%
Tyson Foods	2.8%
Johnson & Johnson	2.7%
ONEOK	2.7%
Gilead Sciences	2.6%

Holdings-based data is subject to change.

Sector allocation (12/31/25)



Consumer Staples	25%
Health Care	19%
Financials	15%
Energy	13%
Information Technology	9%
Industrials	7%
Materials	6%
Consumer Discretionary	5%

[1] The Russell 1000 Index tracks the performance of the 1,000 largest stocks in the Russell 3000 Index, which consists of the 3,000 largest U.S. companies as measured by market capitalization.
[2] Russell 1000 Value Index tracks the performance of those Russell 1000 Index stocks with lower price-to-book ratios and lower forecasted growth values.
[3] Beta is a historical measurement of a fund's sensitivity to the movements of the fund's benchmark index. A fund with a beta greater than one is more volatile than the benchmark. A fund with a beta less than one is less volatile. Beta is based on a three-year period relative to the index. Average market capitalization measures the size of the companies in which the fund invests. Sharpe ratio is a measure of returns reward per unit of risk for a given period. A high sharpe ratio reflects a strong historical risk-adjusted performance. Standard deviation is a three-year statistical measure of the volatility of a fund's returns. Generally, the greater the standard deviation, the greater the fund's volatility. [§]Source: Morningstar, Inc. as of 11/30/2025.

War, terrorism, sanctions, economic uncertainty, trade disputes, public health crises and related geopolitical events have led and, in the future, may lead to significant disruptions in U.S. and world economies and markets, which may lead to increased market volatility and may have significant adverse effects on the fund and its investments.

Fund risk: Stocks may decline in value. The fund will be managed using the CROCI® Investment Process which is based on portfolio management's belief that, over time, stocks which display more favorable financial metrics (for example, the CROCI® Economic P/E Ratio) as generated by this process may outperform stocks which display less favorable metrics. This premise may not prove to be correct and prospective investors should evaluate this assumption prior to investing in the fund. Dividends are not guaranteed. If the dividend-paying stocks held by the fund reduce or stop paying dividends, the fund's ability to generate income may be adversely affected. Preferred stocks, a type of dividend-paying stock, present certain additional risks. The fund may lend securities to approved institutions. Please read the prospectus for details.
Consider the investment objective, risks, charges and expenses carefully before investing. For a summary prospectus, or prospectus that contains this and other information, download one from www.dws.com or talk to your financial representative. Read the prospectus carefully before investing.

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc., which offers investment products, or DWS Investment Management Americas, Inc. and RREEF America L.L.C., which offer advisory services.

Investment products: No bank guarantee | Not FDIC insured | May lose value

DWS Distributors, Inc. 222 South Riverside Plaza, Chicago, IL 60606-5808 | www.dws.com | service@dws.com | Tel (800) 621-1148